Dr. Siwen Hu-Lieskovan

Dr. Siwen Hu-Lieskovan, MD, PhD, is a nationally recognized medical oncologist specializing in melanoma, lung cancer, and early-phase clinical trials in immuno-oncology. She serves as Director of Solid Tumor Immunotherapy and Co-Leader of the Experimental Therapeutics Program at Huntsman Cancer Institute, University of Utah, where she is also an Associate Professor of Medicine. Dr. Hu-Lieskovan earned her medical degree from Tongji Medical University in China and her PhD in molecular pharmacology and toxicology from the University of Southern California. She completed residency in internal medicine at UCLA Medical Center and fellowship training in hematology/oncology at UCLA. She is board-certified in Internal Medicine and Medical Oncology.

Dr. Hu-Lieskovan is a leading investigator in translational immuno-oncology, with research focused on mechanisms of resistance to immune checkpoint inhibitors and novel therapeutic combinations. She has been principal investigator on early-phase clinical trials evaluating checkpoint blockade, adoptive cell therapies, and biomarker-driven immunotherapy approaches. Her work has been published in high-impact journals, and she has been recognized for advancing the field of precision immuno-oncology, particularly in melanoma and thoracic cancers.

In addition to her research leadership, Dr. Hu-Lieskovan is an accomplished mentor and educator, training physician–scientists in translational oncology. She has served on committees for ASCO and AACR and is frequently invited to present her work nationally and internationally. Through her dedication to clinical care, scientific discovery, and mentorship, Dr. Siwen Hu-Lieskovan is shaping the future of immuno-oncology and translational cancer research.